US2666770A - Alkaline cleavage of pseudosapogenin oxidation products - Google Patents

Alkaline cleavage of pseudosapogenin oxidation products Download PDF

Info

Publication number
US2666770A
US2666770A US338172A US33817253A US2666770A US 2666770 A US2666770 A US 2666770A US 338172 A US338172 A US 338172A US 33817253 A US33817253 A US 33817253A US 2666770 A US2666770 A US 2666770A
Authority
US
United States
Prior art keywords
pseudosapogenin
oxidized
alkali
oxidation products
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US338172A
Inventor
Monroe E Wall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US338172A priority Critical patent/US2666770A/en
Application granted granted Critical
Publication of US2666770A publication Critical patent/US2666770A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Definitions

  • An object of this invention is to provide an with this third step that the present invention is improved process for making n -pregnenolones concerned.
  • step 3 the cleavage isbest accomplished in a One of the facts that makes steroidal sapohomogeneous solution containing the alkali and genins'useful for the production of cortisone and the oxidized pseudosapogenin.
  • the solvent used sex hormones is that they are convertible to Ale. should readily dissolve the alkali and oxidized pregnenolones. This conversion is conventionally seudosapogenin and should be inert to them and carried out in three steps as is illustrated below the final product.
  • Methanol and ethanol the
  • the sapogenin is heated at about 200 produce large amounts of the undesirable 16- C. with. acetic anhydride to open ring F.
  • step alkoxy derivatives thus lowering the yield of 2 the resulting pseudosapogenin is oxidized with the desired products.
  • step I the conventional procedure is to cleave the tioned undesired-side reaction can be eliminated ester linkages in the oxidized pseudosapogenin and the yield and purity of thedesired
  • a pregiienolones can be greatly increased by proper choice of the solvent used in step 3 of the process outlined above.
  • Suitable solvents include the tertiary alkanols having not more than six carbon atoms, pyridine and the lower alkyl pyridines. The higher homologs of these soluents are unsuitable because they do not readily dissolve alkali.
  • the suitable solvents can be used in the pure form but their suitability is increased by the addition of not more than about 5% of water.
  • reaction mixture may be warmed if desired, I have found that the reaction proceeds rapidly and smoothly at ordinary room temperature and that heating sometimes lowers the yield of the desired product.
  • reaction mixture need not be entirely homogeneous, provided that adequate agitation and mixing is provided.
  • the entire amount of alkali or oxidized pseudosapogenin need not be dissolved, provided that there is appreciable solubility, because that part which is dissolved will react and be consumed, thus allowing more to be dissolved. In this way the entire amount is soon used up and the overall efiect is almost as good as if the mixture had been homogeneous.
  • Example I Twenty grams of diosgenin acetate and 100 ml. of acetic anhydride were heated hours at 200 C. in a sealed vessel. After being cooled, the acetic anhydride was distilled in vacuum and the remaining pseudosapogenin was dissolved in 200 ml, of acetic acid to which 5 g. of sodium acetate had been added. A solution of 8 g. of chromium trioxide in 30 ml. of 80% aqueous acetic acid was added dropwise, with agitation and cooling, over a period of 30 minutes and at a temperature of about C. The reaction mixture was then allowed to stand 1 hr.
  • the resultant mixture was vigorously stirred at room temperature (ZS-28 C.) for 3 hr., after which two volumes of water were added and the mixture was extracted with ether. After being washed with water the ether solution was evaporated to dryness and the solid residue was dissolved in ml. of pyridine to which was added 25 ml. of acetic anhydride. After being left overnight the resultant A -pregnadien-3s-o1-3-acetoxy-20-one was recovered by diluting with water and extracting with ether. The ether extract was washed with dilute hydrochloric acid, dilute sodium bicarbonate and water; dried with anhydrous sodium sulfate and evaporated to dryness.
  • Example II By proceeding substantially as in Exampl I sarsasapogenin acetate was converted to A pregnen-3fi-ol-3-acetate-20one.
  • Example IV By proceeding substantially as in Example I hecosenin acetate was converted to A -allopregnen-3B-ol-3-acetate-12,20-dione.
  • Example V Ten grams of oxidized pseudotigogenin were dissolved in a pyridine solution prepared by shaking 1 liter of pyridine with 1 liter of 5% aqueous potassium hydroxide and discarding the aqueous layer. After being stirred for 3 hr., an equal volume of water was added to the solution and the Whole was extracted with ether. The ether extract was washed, dried and evaporated and the product was acetylated and chromatographed as in Example I to yield 3.0 g. of A allopregnen-3fi-ol-3-acetate-20-one.
  • a process for making a A -pregnenolone from a steroidal sapogenin comprising cleaving an oxidized pseudosapogenin by the ac tion of alkali in a solvent selected from the group consisting of aliphatic tertiary alcohols having not more than six carbon atoms, pyridine and lower alkylypyridines.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Description

Patented Jan( 19 1954- A A r I ALKALINE CLEAVAGE F PSEUDOSAPO- GENIN OXIDATION PRODUCTS Monroe E. Wall, Oreland, Pa.,, assignor to the United States of America as represented by the Secretary of Agriculture No Drawing. Application February 20, 1953, Serial No. 338,172
7 Claims. (01. 260-89741) (Granted under Title 35, U. S. Codev (1 952),
I see. 266) p A non-exclusive, irrevocable, royalty-free by the action of either acid or alkali in a I license intheinvention herein described, for all methanolic or ethanolic solution. As indicated, governmental purposes, throughout the world, the yield in this step is very poor, usually about with the power to grant sublicenses for such pur- 30%, because of the formation of large amounts poses, is hereby granted to the Government of 5 of the undesirable ld-methoxyor ld-ethoxy dethe United States of America. rivatives by reaction of the desired zi -pregneno- This invention is related to the conversion of lone with the methanol or ethanol used as a solsapogenins to n -pregnenolones. uent'and reaction medium in this step. It: is
An object of this invention is to provide an with this third step that the present invention is improved process for making n -pregnenolones concerned.
from sapogenins. I In step 3 the cleavage isbest accomplished in a One of the facts that makes steroidal sapohomogeneous solution containing the alkali and genins'useful for the production of cortisone and the oxidized pseudosapogenin. The solvent used sex hormones is that they are convertible to Ale. should readily dissolve the alkali and oxidized pregnenolones. This conversion is conventionally seudosapogenin and should be inert to them and carried out in three steps as is illustrated below the final product. Methanol and ethanol, the
with smilagenin, a typical steroidal sapogenin. preferred solvents of the prior art, have suit- Other steroidal sapogenins react in the same way able solvent properties but are not chemically to yield analogous A -p'regnenolones. I inert. They react with the A -pregnenolones to CH3 0H3 (13H:
F -CH3 -(QH rCH-OEQOAC E t 0 E l /O 0 A Step 1 D D. 5
AcO,
Sapogenin (smilagenin) P seudosapogenin [Step2 on; 3 11;- C==OA pre enolone (i=0: I I CHa-.,
Oxidized pseudosapogcnin I! O R l6alkoxy derivative In ste 1 the sapogenin is heated at about 200 produce large amounts of the undesirable 16- C. with. acetic anhydride to open ring F. In step alkoxy derivatives, thus lowering the yield of 2 the resulting pseudosapogenin is oxidized with the desired products. chromium trioxide to open ring E. Then, in step I have now discovered that the above-men- 3, the conventional procedure is to cleave the tioned undesired-side reaction can be eliminated ester linkages in the oxidized pseudosapogenin and the yield and purity of thedesired A pregiienolones can be greatly increased by proper choice of the solvent used in step 3 of the process outlined above. Suitable solvents include the tertiary alkanols having not more than six carbon atoms, pyridine and the lower alkyl pyridines. The higher homologs of these soluents are unsuitable because they do not readily dissolve alkali. The suitable solvents can be used in the pure form but their suitability is increased by the addition of not more than about 5% of water. This greatly increases the solubility of alkali in the solvent but at the same time it decreases the solubility of the oxidized pseudosapogenin being treated. Hence, in practice, the optimum amount of water will be found to depend on the solvent, the alkali and the sapogenin used. While any alkali metal hydroxide, carbonate or bicarbonate can be used, I prefer to use potassium hydroxide because of its ready solubility and its high reactivity.
While the reaction mixture may be warmed if desired, I have found that the reaction proceeds rapidly and smoothly at ordinary room temperature and that heating sometimes lowers the yield of the desired product.
It has also been observed that the reaction mixture need not be entirely homogeneous, provided that adequate agitation and mixing is provided. Thus, the entire amount of alkali or oxidized pseudosapogenin need not be dissolved, provided that there is appreciable solubility, because that part which is dissolved will react and be consumed, thus allowing more to be dissolved. In this way the entire amount is soon used up and the overall efiect is almost as good as if the mixture had been homogeneous.
Example I Twenty grams of diosgenin acetate and 100 ml. of acetic anhydride were heated hours at 200 C. in a sealed vessel. After being cooled, the acetic anhydride was distilled in vacuum and the remaining pseudosapogenin was dissolved in 200 ml, of acetic acid to which 5 g. of sodium acetate had been added. A solution of 8 g. of chromium trioxide in 30 ml. of 80% aqueous acetic acid was added dropwise, with agitation and cooling, over a period of 30 minutes and at a temperature of about C. The reaction mixture was then allowed to stand 1 hr. at room temperature, after which an equal volume of water was added, the excess chromic acid was neutralized with 3 g. of sodium bisulfite and the mixture was extracted with ether. After being washed with dilute sodium bicarbonate and with water, the ether solution was evaporated to dryness, leaving a sirupy residue of oxidized pseudosapogenin. This was dissolved in 500 ml. of tertiary-butanol. To this solution was added a solution of g. of potassium hydroxide and 20 g. of water in 500 m1. of tertiary-butanol. The resultant mixture was vigorously stirred at room temperature (ZS-28 C.) for 3 hr., after which two volumes of water were added and the mixture was extracted with ether. After being washed with water the ether solution was evaporated to dryness and the solid residue was dissolved in ml. of pyridine to which was added 25 ml. of acetic anhydride. After being left overnight the resultant A -pregnadien-3s-o1-3-acetoxy-20-one was recovered by diluting with water and extracting with ether. The ether extract was washed with dilute hydrochloric acid, dilute sodium bicarbonate and water; dried with anhydrous sodium sulfate and evaporated to dryness. The
crude product thus obta ned was purified by dissolving it in benzene and chromatographing it on Florosil (magnesium silicate) The final product was 10.74 g. of M -pregnadien-35-ol-3-acetoxy-20-one which by ultraviolet assay was found to be 94% pure. Recrystallization from methanol yielded 8.5 g. of substantially 100% pure material, The yield, based on the ultraviolet assay, was 74.5% of the theoretical from diosgenin acetate of purity.
Example II Example III By proceeding substantially as in Exampl I sarsasapogenin acetate was converted to A pregnen-3fi-ol-3-acetate-20one.
Example IV By proceeding substantially as in Example I hecosenin acetate was converted to A -allopregnen-3B-ol-3-acetate-12,20-dione.
Example V Ten grams of oxidized pseudotigogenin were dissolved in a pyridine solution prepared by shaking 1 liter of pyridine with 1 liter of 5% aqueous potassium hydroxide and discarding the aqueous layer. After being stirred for 3 hr., an equal volume of water was added to the solution and the Whole was extracted with ether. The ether extract was washed, dried and evaporated and the product was acetylated and chromatographed as in Example I to yield 3.0 g. of A allopregnen-3fi-ol-3-acetate-20-one.
I claim:
1. In a process for making a A -pregnenolone from a steroidal sapogenin, the steps comprising cleaving an oxidized pseudosapogenin by the ac tion of alkali in a solvent selected from the group consisting of aliphatic tertiary alcohols having not more than six carbon atoms, pyridine and lower alkylypyridines.
2. The process of claim 1 wherein the solvent is tertiary butanol.
3. The process of claim 1 wherein the solvent is pyridine.
4:. The process for making a A -pregnenolone from an oxidized pseudosapogenin which comprises treating the oxidized pseudosapogenin with an alkali in a solvent selected from the group consisting of aliphatic tertiary alcohols, pyridine and lower alkylpyridines.
5. The process of claim 4 wherein the alkali is potassium hydroxide.
6. The process of claim 4 wherein the solvent i tertiary butanol.
'7. The process of claim 4 wherein the solvent is pyridine.
MONROE E. WALL.
No references cited.

Claims (1)

1. IN A PROCESS FOR MAKING A $16-PREGNENOLONE FROM A STEROIDAL SAPOGENIN, THE STEPS COMPRISING CLEAVING AN OXIDIZED PSEUDOSAPOGENIN BY THE ACTION OF ALKALI IN A SOLVENT SELECTED FROM THE GROUP CONSISTING OF ALIPHATIC TERTIARY ALCOHOLS HAVING NOT MORE THAN SIX CARBON ATOMS, PYRIDINE AND LOWER ALKYLYPYRIDINES.
US338172A 1953-02-20 1953-02-20 Alkaline cleavage of pseudosapogenin oxidation products Expired - Lifetime US2666770A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US338172A US2666770A (en) 1953-02-20 1953-02-20 Alkaline cleavage of pseudosapogenin oxidation products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US338172A US2666770A (en) 1953-02-20 1953-02-20 Alkaline cleavage of pseudosapogenin oxidation products

Publications (1)

Publication Number Publication Date
US2666770A true US2666770A (en) 1954-01-19

Family

ID=23323689

Family Applications (1)

Application Number Title Priority Date Filing Date
US338172A Expired - Lifetime US2666770A (en) 1953-02-20 1953-02-20 Alkaline cleavage of pseudosapogenin oxidation products

Country Status (1)

Country Link
US (1) US2666770A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2716125A (en) * 1953-10-14 1955-08-23 Merck & Co Inc 3(beta)-acetoxy-16(delta-acetoxyisocaprooxy)-allopregnanedione-11, 20
US2727907A (en) * 1953-11-19 1955-12-20 Searle & Co Derivatives of 16-alkanoyloxy-17alpha-hydroxypregnen-20-ones
US2727909A (en) * 1954-10-12 1955-12-20 Searle & Co 16alpha,17alpha-dihydroxypregnen-20-one derivatives
US2756179A (en) * 1953-04-20 1956-07-24 Olin Mathieson Production of delta 1 bonds in the a ring of the cyclopentanopolyhydrophenanthrene nucleus by streptomyces lavendulae
US2777864A (en) * 1954-07-19 1957-01-15 American Cyanamid Co 16-oxy-cortisone, 16-oxy-hydrocortisone and process
US2885411A (en) * 1959-05-05 Process for the conversion of steroidal
US2897219A (en) * 1953-06-12 1959-07-28 Ciba Pharm Prod Inc delta5-20-keto-3:16:21-trihydroxy-pregnenes and esters thereof
US2929826A (en) * 1957-02-25 1960-03-22 Ciba Pharm Prod Inc Process for preparation of 20-keto-16-pregnenes from 16-acyloxy-20-keto pregnanes
US2971964A (en) * 1958-03-04 1961-02-14 Edward S Rothman Preparation of 11alpha-hydroxy progesterone
US3055918A (en) * 1954-02-25 1962-09-25 Pfizer & Co C alpha-epoxy unsaturated compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885411A (en) * 1959-05-05 Process for the conversion of steroidal
US2756179A (en) * 1953-04-20 1956-07-24 Olin Mathieson Production of delta 1 bonds in the a ring of the cyclopentanopolyhydrophenanthrene nucleus by streptomyces lavendulae
US2897219A (en) * 1953-06-12 1959-07-28 Ciba Pharm Prod Inc delta5-20-keto-3:16:21-trihydroxy-pregnenes and esters thereof
US2716125A (en) * 1953-10-14 1955-08-23 Merck & Co Inc 3(beta)-acetoxy-16(delta-acetoxyisocaprooxy)-allopregnanedione-11, 20
US2727907A (en) * 1953-11-19 1955-12-20 Searle & Co Derivatives of 16-alkanoyloxy-17alpha-hydroxypregnen-20-ones
US3055918A (en) * 1954-02-25 1962-09-25 Pfizer & Co C alpha-epoxy unsaturated compounds
US2777864A (en) * 1954-07-19 1957-01-15 American Cyanamid Co 16-oxy-cortisone, 16-oxy-hydrocortisone and process
US2727909A (en) * 1954-10-12 1955-12-20 Searle & Co 16alpha,17alpha-dihydroxypregnen-20-one derivatives
US2929826A (en) * 1957-02-25 1960-03-22 Ciba Pharm Prod Inc Process for preparation of 20-keto-16-pregnenes from 16-acyloxy-20-keto pregnanes
US2971964A (en) * 1958-03-04 1961-02-14 Edward S Rothman Preparation of 11alpha-hydroxy progesterone

Similar Documents

Publication Publication Date Title
US2666770A (en) Alkaline cleavage of pseudosapogenin oxidation products
Andre et al. Direct Introduction of Oxygen into the Steroid Nucleus. I. Studies on the Chromic Anhydride Oxidation of Dehydroisoandrosterone Acetate Dibromide1
US2153700A (en) Pregnanone compounds and a method of producing the same
US2805230A (en) Esters of 17alpha-hydroxy progesterone
US2256500A (en) Manufacture of pregnendiones
DE1468035A1 (en) Process for the preparation of 19-alkyl steroids
US2352568A (en) Compounds of the saturated and unsaturated cyclopentanopolyhydrophenanthrene-series and derivatives thereof, and process of preparing same
US2777843A (en) Preparation of 4-pregnen-17alpha-ol-3, 20-dione
US2716125A (en) 3(beta)-acetoxy-16(delta-acetoxyisocaprooxy)-allopregnanedione-11, 20
US2745852A (en) Delta4, 16-pregnadiene-21-ol-3, 20-diones and process
US2783254A (en) Process for the manufacture of 17alpha-hydroxycorticosterone and intermediates obtained thereby
US3096350A (en) 6, 16alpha-dimethyl-delta1, 4, 6-pregnatriene-17alpha-ol-3, 20-dione and esters thereof
US2304837A (en) Hydroxy pregnane derivatives and preparation of same
US3684674A (en) Process for preparing 18-cyano-pregnane compounds
US2875201A (en) Dehydrotigogenone intermediates
NO121103B (en)
CH494213A (en) Gona-4 9-dien-3-ones
DE2237202A1 (en) PROCESS FOR THE PRODUCTION OF 17 (2-HALOAETHYLIDEN) STEROIDS
US3080381A (en) Optionally 6-methylated and optionally 17-alkanoyloxygenated 2-oxapregnane-3, 20-diones, a-homo compounds corresponding, and 4, 5-dehydro and 4, 5; 6, 7-bisdehydro derivatives thereof
US2175220A (en) Androstendione and a method of producing the same
CH539621A (en) 15 16 beta-methylene-steroids
US2779774A (en) 3beta-oxy-delta16-allopregnenedione-11, 20 and process
US2794814A (en) 4, 16-pregnadiene-3, 11, 20-trione and process
US3068243A (en) 2-keto-delta3, (5) a-norcortisones
US3164616A (en) Process for preparing delta11-steroid compounds